Exparel Phase III Trial Fails to Meet Primary Endpoint
mia.burns
EXPAREL Phase 3 Clinical Trial in Intercostal Nerve Block Does Not Meet Primary Endpoint
Based upon Ongoing Femoral Nerve Block Trial, sNDA Submission Still Planned ...
Hemispherx Biopharma Appoints Peter W. Rodino III
barbara.lempert
Hemispherx Biopharma Appoints Peter W. Rodino III, Esq. to the Board of Directors and to Serve as Chairman of the Company’s Audit Committee
PHILADELPHIA, July ...
Actelion enters into an agreement to acquire privately-held Ceptaris Therapeutics
barbara.lempert
VALCHLOR(TM) gel under FDA Review for Early-Stage Mycosis Fungoides-Type CTCL
ALLSCHWIL/BASEL, SWITZERLAND and MALVERN, PA – 31 July 2013 – Actelion US ...
Naurex Announces Issuance of New Patent for Novel Antidepressant Glyx-13
barbara.lempert
—Extends Patent Life to 2030 for Novel Agent that Demonstrated Rapid Onset, Robust Efficacy and Good Safety in a Phase II Trial— EVANSTON, IL – July 30, ...
IntelligentMDx Receives FDA Clearance for IMDx VanR for Abbott m2000 assay
barbara.lempert
IntelligentMDx (privately held) announced today that the U.S. Food and Drug Administration (FDA) has cleared its automated molecular diagnostic test that detects the ...
Moody’s cuts GlaxoSmithKline outlook, citing billions in outlays
Tracy Staton
As if GlaxoSmithKline didn't have enough trouble on its hands, Moody's Investors Service has cast some dark clouds over its credit outlook. The agency cut the outlook ...
BioClinica Appoints New EVP and President for Imaging Core Lab Division
mia.burns
David S. Herron Joins BioClinica to Lead Imaging Core Lab Division
– Heads World’s Largest, Most Experienced Imaging Core Lab Operations –
NEWTOWN, PA, July ...
Class-Action Suit Against Pfizer Over Anti-Smoking Drug Champix Will Proceed
barbara.lempert
OTTAWA, Canada, July 26, 2013 (CANADIAN PRESS DATAFILE) – A class-action lawsuit against pharmaceutical giant Pfizer Canada over its anti-smoking drug ...
Court overturns patents on Teva’s MS drug Copaxone
barbara.lempert
NEW YORK, July 26, 2013 (AP) — Two drug companies said Friday that they hope to start selling a generic version of the multiple sclerosis treatment Copaxone ...
Five Prime Therapeutics pitches $60M IPO after string of pharma collaborations
Ryan McBride
Five Prime Therapeutics wants to follow more than two dozen other drug developers this year onto the public market. The South San Francisco-based biotech, a developer of ...
GSK China Boss Replaced in Wake of Scandal
mia.burns
GlaxoSmithKline has replaced the British head of its Chinese operations, which are at the centre of a pounds 320m cash and sexual bribery scandal.
Britain’s ...